Global Cystitis Market
Sizing, Segmentation, & Growth Forecast (2025-2030)
Last updated: August 2026
Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.
Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).
1. Summary
The Global Cystitis Market was valued at $2.0 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 9.2% CAGR, to an estimated market size of $3.2 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.
2. Market Definition
The Global Cystitis Market encompasses the diagnosis, management, and treatment of bladder inflammation, including Interstitial Cystitis (IC/Bladder Pain Syndrome), Hemorrhagic Cystitis, and Infectious Cystitis. The scope includes pharmacological therapies (oral and intravesical), neuromodulation devices, and procedural interventions, while excluding primary urinary tract infections (UTIs) that do not progress to clinical cystitis.
3. Trends & Demand Drivers
Several key trends are expected to significantly impact the Cystitis Market in the period 2025-30:
- The therapeutic landscape is shifting from symptomatic relief toward mechanism-based interventions, with over half of new clinical trials focusing on biologic therapies.
- Significant diagnostic gaps persist, with patients experiencing an average delay of three to seven years before receiving a formal diagnosis of interstitial cystitis.
- Safety concerns regarding retinal toxicity associated with long-term use of pentosan polysulfate sodium are driving a decline in its utilization among older patient populations.
- There is a growing adoption of multimodal care models that integrate pharmacological treatments with pelvic floor therapy and dietary modifications to manage chronic symptoms.
- The rising prevalence of pelvic malignancies is increasing the incidence of treatment-induced hemorrhagic cystitis, creating a higher demand for specialized supportive care.
- Advancements in minimally invasive therapies, including botulinum toxin injections and nerve stimulation, are expanding options for patients with refractory cystitis.
- Increased healthcare expenditure and improved diagnostic infrastructure in emerging markets, particularly in Asia-Pacific, are accelerating regional market growth.
4. Market Breakdown
The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:
Geographies
- North America
- Europe
- Asia-Pacific
- Rest of World
Segments
- Oral Therapies
- Intravesical Instillations
- Other (Neuromodulation & Surgery)